BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Radient Pharmaceuticals Chinese Pharma Division Has Put in Place a Strategic Advisory Agreement With Security Research Associates Inc. to Assist With the Sale or Financing of Jade Pharmaceutical, Inc.


12/18/2009 10:04:19 AM

TUSTIN, CA--(Marketwire - December 18, 2009) - US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today its China-based subsidiary Jade Pharmaceutical, Inc. ("JPI"), of which RPC owns approximately 98%, has signed a strategic advisory agreement with Security Research Associates, Inc. ("SRA").

Under the terms of the agreement, SRA will provide advisory services to RPC for the sale and/or financing of JPI, with the goal of maximizing the monetization of this operating asset. As of RPC's Q309 financial statements, JPI is valued at approximately $20.5 million on RPC's balance sheet.

SRA is a boutique investment banking and capital markets firm that supports fast-growing, publicly-traded companies in the small cap arena. SRA is specifically focused on companies having between a $50 million -- $2 billion market capitalization in the technology, healthcare, consumer and cleantech sectors.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals Corporation, "We are extremely pleased JPI has retained SRA to assist them in executing a sale or strategic financing, which is currently slated in early FY2010. Our goal is to maximize the monetization of this operating asset on behalf of the shareholders of JPI."

For additional information on Radient Pharmaceuticals or JPI visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Ms. Kristine Szarkowitz at kszarkowitz@Radient-Pharma.com or 1.206.310.5323.

Additional information on SRA is available at www.sracap.com or by contacting Mr. Gary Hamilton, managing Director at garyh@sracap.com or 1-203-702-4498.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.


AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
Tel: 206.310.5323

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES